Entropix secures investment from LYVA Labs

By Evie Ransome

Enzyme development company, Entropix has secured investment from LYVA Labs.

Entropix, a company creating high-performance enzymes for use across a range of sectors, described the investment as a “six-figure” sum.

LYVA Labs was established with £11m from Liverpool City Region’s Combined Authority, to drive innovation and economic growth by turning great ideas into high- growth businesses and creating partnerships to attract investment.

Entropix was co-founded in 2021 by Dr Rob Rule and Professor David Hornby, who have an international reputation in enzyme technology, which they say is part of a $12billion
market opportunity.

The investment from LYVA Labs will enable them to continue to scale their activities and to grow their science team and research activity.

Speaking of the investment, Rob Rule, CEO Entropix Ltd, said: “This investment from LYVA Labs is testament to the progress we have made since our earlier investment from Deepbridge Capital. We have been developing our technology platform and a range of high-performance enzymes during this time. The company is ready to commercialise its own enzymes in the life science sector and has several opportunities in the pipeline to develop enzymes for a range of customers.”

Pictured: Dr Rob Rule, CEO and Co-founder, Entropix; Professor David Hornby, Chief Scientific Officer (CSO) and Co-founder, Entropix; Rachel Lawless, Innovation Funding Manager, LYVA Labs; Akshay Bhatnagar, Head of Investments, LYVA Labs